Supernus Pharmaceuticals (SUPN) Short-term Investments (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Short-term Investments data on file, last reported at $199.4 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $199.4 million, down 42.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $199.4 million (down 42.67% YoY), and the FY2025 annual result was $180.2 million, down 53.1% from the prior year.
• Short-term Investments advanced to $199.4 million in Q1 2026 per SUPN's latest filing, from $180.2 million in the prior quarter.
• Over five years, Short-term Investments peaked at $384.3 million in Q4 2024 and troughed at $105.2 million in Q3 2023.
• A 5-year average of $243.2 million and a median of $199.4 million in 2026 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments jumped 253.16% in 2024, then sank 65.07% in 2025.
• A 5-year view of Short-term Investments shows it stood at $368.2 million in 2022, then sank by 51.16% to $179.8 million in 2023, then soared by 113.7% to $384.3 million in 2024, then slumped by 53.1% to $180.2 million in 2025, then advanced by 10.63% to $199.4 million in 2026.
• Business Quant data shows SUPN's Short-term Investments at $199.4 million in Q1 2026, $180.2 million in Q4 2025, and $129.8 million in Q3 2025.